Ionis director granted RSUs and stock options
IONIS PHARMACEUTICALS INC director Joan E. Herman received new equity awards as part of non-employee director compensation.
Rhea-AI Filing Summary
IONIS PHARMACEUTICALS INC director Joan E. Herman received new equity awards as part of non-employee director compensation. On July 1, 2026, Herman was granted 2,301 Restricted Stock Units, each representing a right to receive one share of Ionis common stock or its cash equivalent, subject to vesting.
On the same date, Herman was also granted options on 5,369 shares of common stock at an exercise price of $79.19 per share. Both the RSUs and options vest 100% on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, consistent with the company’s non-employee director compensation policy that caps 2026 equity compensation at $400,000 based on grant-date fair value.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 7,670 shares
Grant/Award
2 txns
Insider
HERMAN JOAN E
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Non-Qualified Stock Option (right to buy) | 5,369 | $0.00 | $0.00 |
| Grant/Award | Restricted Stock Unit | 2,301 | $0.00 | $0.00 |
Holdings After Transaction:
Non-Qualified Stock Option (right to buy) — 5,369 contracts (Direct);
Restricted Stock Unit — 7,521 contracts (Direct)
Footnotes (4)
- F1. Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.
- F2. Grant on July 1, 2026 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2026.
- F3. Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
- F4. Grant on July 1, 2026 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2026.
Key Figures
RSU grant size: 2,301 units
Options granted: 5,369 options
Option exercise price: $79.19 per share
+2 more
5 metrics
RSU grant size
2,301 units
Restricted Stock Units granted on July 1, 2026
Options granted
5,369 options
Non-Qualified Stock Options granted on July 1, 2026
Option exercise price
$79.19 per share
Exercise price for new stock options
RSUs after grant
7,521 units
Total Restricted Stock Units following transaction
2026 equity comp cap
$400,000
Annual equity cap for non-employee directors based on grant-date fair value
Key Terms
Restricted Stock Unit, Non-Qualified Stock Option, FASB Topic ASC 718, Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan
4 terms
Restricted Stock Unit financial
"Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Non-Qualified Stock Option financial
"Grant on July 1, 2026 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
FASB Topic ASC 718 financial
"annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718"
Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan financial
"Grant on July 1, 2026 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan"
FAQ
What equity awards did IONIS (IONS) director Joan E. Herman receive?
Joan E. Herman received 2,301 Restricted Stock Units and stock options on 5,369 shares. Both awards were granted on July 1, 2026 as part of non-employee director compensation.
What is the exercise price of the new IONIS (IONS) stock options?
The new stock options have an exercise price of $79.19 per share. Herman can purchase Ionis common stock at this price once the options vest and become exercisable under the award terms.
When do Joan E. Herman’s new IONIS (IONS) equity awards vest?
Both the RSUs and options vest 100% on the earlier of the first anniversary of the July 1, 2026 grant or the next annual stockholder meeting, aligning with the director compensation plan.
How many Restricted Stock Units does Joan E. Herman hold after this IONIS (IONS) grant?
After this transaction, Herman holds 7,521 Restricted Stock Units. Each unit represents a contingent right to receive one share of Ionis common stock or its equivalent cash value upon settlement.
How is IONIS (IONS) director equity compensation limited for 2026?
The company’s non-employee director compensation policy caps a director’s 2026 annual equity compensation at $400,000. This cap is based on aggregate grant-date fair value calculated under FASB Topic ASC 718.
AI-generated analysis. How Rhea-AI works. Not financial advice.
